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Background: ST2, a member of the interleukin (IL)-1receptor family, regulates Th1/Th2 immune responses in
autoimmune and inflammatory conditions. However, the role of ST2 signaling in tumor growth and metastasis of
breast cancers has not been investigated. This study investigated the possible role of soluble ST2 (sST2) in breast
cancer.
Methods: The serum levels of IL-33, sST2, and vascular endothelial growth factor (VEGF) in 150 breast cancer
patients and 90 healthy women were measured by enzyme-linked immunosorbent assay. Estrogen receptor(ER),
progesterone receptor, human epithelial receptor (HER)-2, and cell cycle regulated protein Ki-67 were measured.
Clinical stage, tumor size, lymph node metastasis, and histological type were also recorded.
Results: The serum levels of sST2, IL-33, and VEGF were significantly higher in breast cancer patients than in the
control group (P < 0.05, each). Serum sST2 levels in ER-positive breast cancer patients were significantly associated
with age, histological type, clinical stage, tumor size, and Ki-67 status (P < 0.05, each). Moreover, the serum levels of
IL-33 and sST2 in breast cancers significantly correlated with VEGF levels (IL-33: r = 0.375, P < 0.0001; sST2: r = 0.164,
P = 0.045). Serum levels of sST2, IL-33, and VEGF decreased after modified radical mastectomy in ER-positive breast
cancers. Serum levels of IL-33, sST2, and VEGF and clinicopathological factors were not significantly correlated with
disease-free survival and overall survival of ER-positive breast cancer women during follow-up.
Conclusion: Serum sST2 levels in ER-positive breast cancer patients are significantly associated with factors that
indicate poor prognosis.
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Breast cancer is one of the most common malignancies
and the leading cause of mortality in women in western
countries and in China [1]. Thus, early diagnosis and
effective therapies for breast cancer are imperative. Dif-
ferential biomarkers are an effective diagnostic method
for screening and targeting breast cancer. However, a
limited number of biomarkers for breast cancer have
been validated for clinical application [2].
ST2 is a member of the interleukin 1 receptor (IL-1R)
family that was originally identified in oncogene or
serum-stimulated fibroblasts [3]. Differential mRNA
processing within the ST2 gene generates three isoforms:* Correspondence: wuyunfei860516@163.com
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reproduction in any medium, provided the ora soluble form, a membrane-anchored form, and a vari-
ant ST2. The soluble ST2 (sST2) is especially found in
embryonic tissues, and is secreted by macrophages, type
2 helper T (Th2) cells, and fibroblasts [4]. IL-33, as
ST2’s natural ligand which is expressed in many tissues,
can induce the secretion of both proinflammatory and
anti-inflammatory cytokines [5]. IL-33 induces angiogen-
esis and vascular permeability through ST2 and multiple
inflammatory angiogenic factors such as vascular endo-
thelial growth factor (VEGF) [6]. IL-33/ST2 signaling
has a protective role against parasites, in atherosclerosis,
and obesity, but it can enhance Th2 and mast cell-
mediated diseases such as asthma and anaphylaxis [7].
Schmieder et al. [8] found that IL-33 might act as a cru-
cial mediator in inflammation-associated pancreatic
carcinogenesis. Jovanovic et al. [9] reported that the
mice lacking ST2 showed slower breast cancer growthThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ST2 in tumor growth and metastasis in breast cancer
patients has not been explored.
In the present study, we investigated whether serum
IL-33 or sST2 correlated with VEGF levels or clinico-
pathological features in breast cancer tissues.
Methods
Patients
The Ethics Committee at First Affiliated Hospital of China
Medical University approved the study, in accordance
with the Declaration of Helsinki. All individuals gave
written informed consent for participation in the study.
Between 2011 and 2013 at First Affiliated Hospital of
China Medical University, we prospectively recruited 150
women aged 51.7 ± 8.4y with high risk of breast cancer de-
termined by imaging diagnosis. The control group con-
sisted of 90 healthy women aged 50.2 ± 8.5y whose ages
were matched to the patient cohort. The breast cancers
met updated criteria for metastatic breast cancer estab-
lished by the National Comprehensive Cancer Network
[10]. The 150 patients had never undergone mastectomy,
breast-conserving surgery, or anticancer medication for
breast cancer. Serum samples were obtained 1–2 weeks
before surgery. Twenty-six patients who underwent modi-
fied radical mastectomy and were not using anticancer
medication were selected 4-6 weeks after surgery based on
estrogen receptor (ER)-positive expression.
Patients were followed up at an interval of 12–24
weeks, with the day pathological diagnosis was per-
formed considered as the first day of follow-up. The 150
patients had been followed up for a median of 73 weeks
(range, 24–121 weeks), during which time there were 9
relapses and 4 deaths. Disease-free survival (DFS) was
defined as the time between surgery and the date of first
local recurrence, distant metastasis, second primary can-
cer of another organ, or death from any cause whichever
appeared first during follow-up. Patients known to be
alive with no evidence of disease were censored at the
last follow-up date. Overall survival (OS) was defined
from surgery to death for any cause, and patients who
were alive were censored at date of last follow-up visit.
The following information was recorded: tumor size,
axillary lymphnode, cancers stage according to the
tumor-node-metastasis classification, histological type,
status of ER and progesterone receptor (PR), human epi-
thelial receptor (HER)-2 protein status and cell cycle
regulated protein Ki-67. All patients’ serum samples
were stored at–80°C before use.
Assay for serum levels of sST2, IL-33, and VEGF
Serum levels of IL-33, sST2, and VEGF were measured
using enzyme-linked immunosorbent assay in accord-
ance with the manufacturer’s directions (R&D systems,Minneapolis, MN, USA). The sensitivities of the immu-
noassays for IL-33 and sST2/VEGF were 33 pg/mL and
23 pg/mL, respectively.
Statistical analysis
All analyses were performed using SPSS18.0 (SPSS,
Chicago, IL) and GraphPad5 software. The data are pre-
sented as the mean ± standard error of the mean. Con-
tinuous variables from the study were analyzed by the
ANOVA and/or the Student’s t test with a parametric
distribution or the Mann–Whitney U test with a non-
parametric distribution. Spearman’s correlation coeffi-
cient was used to test the correlations between two
variables. Disease-free survival and overall survival were
estimated using the Kaplan–Meier method and Cox
regression analyses. The hazard ratios and corresponding
95% confidence intervals (CIs) were calculated with Cox’s
proportional hazards model. A P < 0.05 was considered
significant.
Results
Serum levels of sST2, IL-33 and VEGF in breast cancer
patients
The serum levels of sST2 in breast cancer patients
(n = 150) and the prevalence of ER-positive breast cancer
patients (103/150, 68.7%) were significantly higher than
those of the control group (100.5 ± 4.1 pg/mL compared
with 67.6 ± 2.9 pg/mL, P < 0.0001; 103.6 ± 5.8 pg/ml
compared with 67.6 ± 2.9 pg/ml, P < 0.0001; Figure 1A),
but sST2 levels in ER-negative breast cancer patients
(47/150, 31.3%) was not significantly different from
those of the healthy controls (73.3 ± 4.1 pg/mL com-
pared with 67.6 ± 2.9 pg/mL, P = 0.2583; Figure 1A).
sST2 levels in ER-positive breast cancer patients were
significantly higher than in ER-negative patients (103.6 ±
5.8 pg/mL compared with 73.3 ± 4.1 pg/mL, P = 0.0011;
Figure 1A). In addition, serum sST2 levels in ER-positive
breast cancer patients were bifurcated at mean value
(103.6 pg/mL).Values of >103.6 pg/mL indicated high
levels of serum sST2 in ER-positive breast cancer patients,
and values of <103.6 pg/mL indicated low levels of serum
sST2.
The serum levels of IL-33 and VEGF in all breast cancer
patients taken together, ER-positive breast cancer patients,
and ER-negative breast cancer patients were significantly
higher than those of the control group (IL-33: 105.5 ±
16.0 pg/mL, 162.0 ± 39.2 pg/mL, 306.0 ± 140.8 pg/mL
compared with 30.7 ± 3.3 pg/mL P < 0.05,each; Figure 1B;
VEGF: 257.6 ± 14.6 pg/mL, 248.5 ± 16.5 pg/mL, 263.1 ±
29.8 pg/mL compared with 93.0 ± 8.6 pg/mL P < 0.05,each;
Figure 1C). IL-33 and VEGF levels in ER-positive breast
cancer patients were not significantly different than those
of the ER-negative patients (IL-33: 162.0 ± 39.2 pg/mL
compared with 306.0 ± 140.8 pg/mL, P = 0.1973, Figure 1AB;
Figure 1 (See legend on next page.)
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Table 1 Clinicopathological implication of sST2 levels
in ER-positive breast cancers
Parameter N (total = 103) sST2-2(pg/ml)
Mean ± SEM p-value
Age (years)
<50 years old 45 75.7 ± 6.6 <0.0001*
≥50 years old 58 125.2 ± 7.9
Histological type
IBC 91 108.1 ± 6.3 0.0307*
DCIS 12 69.0 ± 11.5
Stage
0 12 69.0 ± 11.5 0.0108*
I 27 96.5 ± 11.8 -
II 49 112.4 ± 9.0 -
III 15 115.0 ± 11.8
Tumor size (cm)
Tis 12 69.0 ± 11.5 0.0165*
T1(≤2) 37 96.9 ± 9.2 -
T2 (>2, ≤5) 50 116.8 ± 9.1
T3 (>5) 4 123.5 ± 8.6 -
Lymphonodus status
Positive 70 97.3 ± 7.2 0.0119
Negative 33 116.8 ± 9.6
PR status
Positive 99 102.6 ± 6.0 0.4439
Negative 4 125.9 ± 16.6
Tissue Her-2
Positive 10 109.9 ± 13.5 0.7252
Negative 93 102.9 ± 6.3
Ki67 status
>14%(+) 74 120.5 ± 6.6 <0.0001*
≤14% (+) 29 60.4 ± 7.7
Abbreviation: No = number, IBC = invasive breast cancer, T = tumor size,
Tis: tumor in situ, DCIS: ductal carcinoma in situ, ER = estrogen receptor,
PR = progesterone receptor, Her-2 = human epithelial receptor-2.
*: p < 0.05.
Numerical data are shown as mean ± standard error P < 0.05, indicated a
significant association.
(See figure on previous page.)
Figure 1 Analysis of the serum levels of sST2, IL-33 and VEGF in breast cancer patients. A. The serum levels of sST2 in breast cancer
patients and the prevalence of ER-positive breast cancer patients (103/150, 68.7%) were significantly higher than those of the control group (P < 0.05,
respectively). B. The serum levels of IL-33 in all breast cancer patients taken together, ER-positive breast cancer patients, and ER-negative breast cancer
patients were significantly higher than those of the control group (all p < 0.05). C. The serum levels of VEGF in all breast cancer patients taken together,
ER-positive breast cancer patients, and ER-negative breast cancer patients were significantly higher than those of the control group (all p < 0.05).
D. The serum levels of sST2 in breast cancer patients had significant correlations with VEGF (r = 0.164, P = 0.045). E. The serum levels of IL-33 in breast
cancer patients had significant correlations with VEGF (r = 0.375, P < 0.0001). F. The serum levels of sST2 significantly decreased after modified radical
mastectomy (P < 0.0001). G. The serum levels of IL-33 significantly decreased after modified radical mastectomy (P = 0.0113). H. Serum levels of VEGF
decreased after therapy (P < 0.0001).Abbreviations: BC=breast cancer, HC=healthy controls, ER=estrogen receptor.
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140.8 pg/mL, P = 0.6455, Figure 1C). In addition, serum
IL-33/VEGF levels in ER-positive breast cancer patients
were bifurcated at mean value (IL-33: 162.0 pg/mL; VEGF:
248.5 pg/mL). Values of >162.0 pg/mL indicated high levels
of serum IL-33 in ER-positive breast cancer patients, and
values of <162.0 pg/mL indicated low levels of serum IL-
33. Values of >248.5 pg/mL indicated high levels of serum
VEGF in ER-positive breast cancer patients, and values of <
thinsp;248.5 pg/mL indicated low levels of serum VEGF.
Association of sST2, IL-33 and VEGF expression levels and
clinical-pathological factors in ER-positive breast cancer
Serum levels of sST2 in invasive breast cancer patients
(n = 91) were significantly higher than those of breast
cancer patients with ductal carcinoma in situ (DCIS, n =
12; 108.1 ± 6.3 pg/mL compared with 69.0 ± 11.5 pg/mL,
P = 0.0307; Table 1). Serum levels of sST2 increased with
increasing tumor size: serum sST2 concentrations of Tis
(n =12), T1 (≤2 cm, n = 37), T2 (>2 cm, ≤5 cm, n = 50),
and T3(>5 cm, n = 4) tumors were 69.0 ± 11.5 pg/mL,
96.9 ± 9.2 pg/mL, 116.8 ± 9.1 pg/mL, and 123.5 ±
48.9 pg/mL, respectively. The sST2 serum levels of pa-
tients with T2 tumors was significantly higher than those
of patients with Tis tumors (P = 0.0165; Table 1).
Serum levels of sST2 increased with increasing stage
of breast cancer. The serum sST2 concentrations of
stage0 (n = 12), stage I (n = 27), stage II (n = 49), and
stage III (n = 15) were 69.0 ± 11.5 pg/mL, 96.5 ± 11.8 pg/
mL, 112.4 ± 9.0 pg/mL, and115.0 ± 11.8 pg/mL, respect-
ively. Serum sST2 levels correlated with stage of ER-
positive breast cancer, with significant differences between
stages 0 and III (P = 0.0108) and between stages II and 0
(P = 0.0275; Table 1).
The serum sST2 levels in ER-positive breast cancer pa-
tients whose age was ≥50y old (125.2. ± 7.9 pg/mL) were
significantly higher than those of younger ER-positive
patients (75.7 ± 6.6 pg/mL, P < 0.0001; Table 1).The serum
concentrations of sST2 in ER-positive breast cancer
patients were not correlated with lymphonodus status
(P > 0.05; Table 1).The serum concentrations of IL-33 and
VEGF in breast cancer patients were not correlated with
age, histological type, tumor size, lymphonodus status, or
stage (P > 0.05).
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Ki-67 in ER-positive breast cancers
Among ER-positive breast cancer patients, those with
high Ki-67 expression (>14%[+]) had significantly higher
serum sST2 levels than did those with low-Ki-67 expression
(120.5 ± 6.6 pg/mL compared with 60.4 ± 7.7 pg/mL,
P < 0.0001, Table 1). However, among these patients
there were no significant differences in PR status or
Her-2 status (both P > 0.05; Table 1).
Correlations of serum levels of sST2/IL-33 and VEGF
The serum levels of sST2 and IL-33 in breast cancer patients
had significant correlations with VEGF (sST2: r= 0.164,
P= 0.045; Figure 1D, IL-33: r= 0.375, P < 0.0001; Figure 1E).
Serum levels of IL-33, sST2, and VEGF decreased after
modified radical mastectomy in patients with ER-positive
breast cancer
Among the 150 patients, 26 ER-positive breast cancer pa-
tients under went modified radical mastectomy. The serum
levels of both IL-33 and sST2 significantly decreased after
modified radical mastectomy (sST2: P < 0.0001, Figure 1F;
IL-33: P = 0.0113, Figure 1G). Serum levels of VEGF also
decreased after therapy (P < 0.0001; Figure 1H).
Serum levels of IL-33, sST2, and VEGF and clinicopathological
factors associated with disease-free survival and overall
survival in patients with ER-positive breast cancer
The 103 patients with ER-positive breast cancer had been
followed up for a median of 73 weeks (range, 24–121
weeks), during which time there were 7 relapses and 3
deaths. Table 2 showed that serum sST2, IL-33 and VEGF
levels were not correlated with disease-free survival of ER-
positive breast cancer women during follow-up (high ver-
sus low) (sST2: HR, 2.371; 95% CI, 0.520-10.812; P = 0.265;
IL-33: HR, 0.988; 95% CI, 0.190-5.126; P = 0.988; VEGF:
HR, 1.308; 95% CI, 0.119-14.437; P = 0.826). Serum sST2,
IL-33 and VEGF levels were not correlated with overall
survival of ER-positive breast cancer women during
follow-up (high versus low) (sST2: HR, 147.956; 95% CI,
0.006-3.743E5; P = 0.334; IL-33: HR, 0.870; 95% CI,
0.078-9.696; P = 0.910; VEGF: HR, 0.516; 95% CI, 0.115-
2.309; P = 0.387; Table 2). All clinicopathological factors
were not correlated with disease-free survival and over-
all survival of ER-positive breast cancer women during
follow-up (all p > 0.05; Table 2).
Discussion
In the present study, we investigated whether serum IL-33
or sST2 correlated with VEGF levels or clinicopathological
features in breast cancer tissues. We used an enzyme-
linked immunosorbent assay to measure serum levels of
IL-33, sST2, and VEGF. Significant associations werefound between sST2 and factors that indicate poor prog-
nosis in ER-positive breast cancer.
We found that serum levels of IL-33 and sST2 in
breast cancer patients were significantly higher than in
healthy women. There are other evidences that IL-33
and sST2 may be involved in the pathogenesis of cancer.
Gillibert et al. [11] showed that serum levels of sST2 in
metastatic breast cancer patients were higher than in
primary breast cancer patients, and our study showed
serum levels of sST2 in primary breast cancer patients
were significantly higher than in healthy women. That
demonstrated high sST2 level might be a risk factor for
breast cancer. According to Küchler et al. [12], IL-33
was generally expressed in the nuclei of resting endothe-
lia, but was rapidly down regulated in tumors. sST2
functions as an antagonistic decoy receptor which serves
as a ligand sink by competing for IL-33 with membrane-
bound ST2 [5]. Therefore, it is not surprising that ele-
vated levels of IL-33 are accompanied by an sST2
upregulation.
Our study also found the serum levels of sST2 in ER-
positive breast cancer patients were significantly higher
than those of the control group, but sST2 levels in ER-
negative breast cancer patients were not significantly dif-
ferent from those of healthy controls. ER is recognized
as an independent prognostic factor in breast cancer,
and recent studies have shown survival advantages
among women with ER-positive tumors relative to
women with ER-negative tumors [13]. Therefore, we
evaluated the sST2 serum levels in ER-positive sub-
groups. Among these subgroups, serum levels of sST2 in
invasive breast cancer patients were significantly higher
than those of DCIS patients, and there was a significant
correlation with age, tumor size, and clinical stage. Our
study found sST2 levels in ER-positive breast cancer pa-
tients did not correlate with the Her-2 status confirms
previous results by Gillibert-Duplantier et al. [11]. We
held same reason for limiting cases (Her-2 positive pa-
tients: 10/103; Table 1). We should enlarge sample size
regarding breast cancer patients in the future study. We
also found that serum sST2 levels in ER-positive breast
cancer patients with high-Ki-67 were significantly higher
than those of the low-Ki-67 group. Sahin et al. [14] dem-
onstrated a strong correlation between the percentage of
cells positive for Ki-67 and nuclear grade, age, and mitotic
rate in breast carcinomas. Therefore, we surmise that
sST2 may also be significantly associated with factors that
indicate poor prognosis in ER-positive breast cancer.
Angiogenesis is inevitable in tumor growth and the
formation of locoregional and systemic metastases. The
role of VEGF in angiogenesis is well recognized, and a
high expression of VEGF indicates in most cases a poor
prognosis [15]; VEGF expressed by endothelial and
tumor cells could be considered a promising target to
Table 2 Clinicopathological factors associated with disease-free survival and overall survival in patients with
ER-positive breast cancer
Parameter N(total = 103) Disease-free survival Overall survival
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (years)
<50 years old 45 1 1
≥50 years old 58 1.352 0.262-6.976 0.719 0.275 0.025-3.037 0.292
Histological type
IBC 91 1 1
DCIS 12 0.044 0.000-1.173E6 0.721 0.044 0.000-2.452E12 0.846
Stage
0, I and II 88 1 1
III 15 1.782 0.345-9.194 0.490 2.218 0.201-24.536 0.516
Tumor size (cm)
≤2 cm 49 1 1
>2 cm 54 0.460 0.096-2.196 0.330 0.136 0.011-1.636 0.116
Lymphonodus status
Positive 70 1 1
Negative 33 2.834 0.539-14.891 0.219 2.366 0.205-27.247 0.490
PR status
Positive 99 1 1
Negative 4 0.046 0.000-6.748E5 0.715 0.046 0.000-9.501E8 0.799
Tissue Her-2
Positive 10 1 1
Negative 93 31.064 0.011-8.581E4 0.395 32.686 0.000-3.286E6 0.533
Ki67 status
>14%(+) 74 1 1
≤14% (+) 29 1.229 0.238-6.339 0.805 1.506 0.0136-16.627 0.738
sST2 status
High 48 1 1
Low 55 2.371 0.520-10.812 0.265 147.956 0.006-3.743E5 0.334
IL-33 status
High 23 1 1
Low 80 0.988 0.190-5.126 0.988 0.870 0.078-9.696 0.910
VEGF status
High 47 1 1
Low 56 1.308 0.119-14.437 0.826 0.516 0.115-2.309 0.387
Abbreviation: No = number, IBC = invasive breast cancer, T = tumor size, Tis: tumor in situ, DCIS: ductal carcinoma in situ, ER = estrogen receptor, PR = progesterone
receptor, Her-2 = human epithelial receptor-2, CI = Confidence interval.
P < 0.05, indicated a significant association.
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several contradictory results reported in the literature on
serum levels of VEGF in breast cancer patients. While
Heer K et al. [16] demonstrated elevated VEGF serum
levels in cancer patients compared to healthy controls
and the correlation between a high concentration of
VEGF, tumor size, and metastasis to regional lymph
nodes, Hodorowicz-Zaniewska et al. [17] did not.Moreover, in the latter study VEGF levels did not correl-
ate with clinicopathological factors. In our study, we
found the serum levels of VEGF were significantly
higher in breast cancer patients than in the control
group, but not correlated with clinicopathological fac-
tors. The composition of the study cohort obviously de-
termines the quality of the outcome measure, which
needs us to enlarge sample size regarding breast cancer
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clusion due to random errors. The present study found
for the first time that serum levels of IL-33 and sST2 in
breast cancer patients had significant correlations with
VEGF. We also found serum levels of IL-33, sST2, and
VEGF decreased after modified radical mastectomy in
patients with ER-positive breast cancer. Whether IL-33,
sST2, and VEGF play a role in the promotion or eradica-
tion of tumors, the tumor immunoregulatory effect on
them is weakened along with tumor disappearance.
The present study evaluated the correlation between
serum sST2 and IL-33 levels and ER-positive breast cancer
patient survival for the first time. We found that serum
levels of IL-33, sST2, and VEGF and clinicopathological
factors were not correlated with disease-free survival and
overall survival of ER-positive breast cancer women dur-
ing follow-up. But the results may not explain this prob-
lem completely because of short follow-up time (a median
of 73 weeks (range, 24–121 weeks)). We should continue
follow-up to give a demonstration.
From the above mentioned evidence, sST2 may imply
a therapeutic target for ER-positive breast cancer. One
study reported that deletion of ST2 signaling enhanced
the antitumor immune response in a murine model of
metastatic breast carcinoma [18]. There is a need to con-
duct more researches in this field to give a demonstration.
Some limitations of the current study should be ac-
knowledged. Firstly, we did not evaluate the interactions
between serum sST2 levels and other therapies (e.g., anti-
cancer medication and endocrine treatment), resulting in a
lack of information showing the value of serum sST2 con-
centration in evaluating effectiveness of those therapies.
Secondly, relatively small sample size regarding breast can-
cer patients, making the results susceptible to false-positive
conclusion due to random errors. Thirdly, short follow-up
time may make the survival data inaccuracy. In addition,
we did not explore sST2 level after anticancer medication
or endocrine treatment in detail, which results in uncer-
tainty on this issue and calls for more studies.
Despite limitations, the current study revealed sST2
involved in the pathogenesis of ER-positive breast cancer.
Conclusion
Serum sST2 levels are higher in ER-positive breast can-
cer patients, and are significantly associated with factors
that indicate poor prognosis.
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